CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS –10/19/2021

F.D.A. to Allow ‘Mix and Match’ Approach for Covid Booster Shots

Why Public Health Faces a Crisis Across the U.S.

AY.4 Delta sub-lineage now predominant in UK and Australia, rising in the US

Changes in Cigarette Sales in the United States During the COVID-19 Pandemic

”…The finding shows a surge in cigarette sales during the COVID-19 pandemic. We estimated an increase of about 0.34 pack per month per capita, corresponding to about a 14.1% increase above the expected sales. Excess sales of cigarettes reported in this study align with findings from Nielsen retail tobacco sales data of increases in tobacco sales from April to June 2020 (4). However, this study shows that increases in cigarette sales went beyond the first 3 months of the COVID-19 pandemic and persisted in the 16 months after its onset in March 2020…”

FROM THE WASHINGTON POST 18 OCT:

”…Colin Powell died at 84 of complications from a coronavirus infection. Powell was vaccinated, though he had several factors for a weakened immune response: He was an elderly man and he had been treated in recent years for multiple myeloma, a blood cancer. This event is no reason to avoid vaccination — in fact, as these charts show, as more people are immunized, the risk of death decreases even among the most vulnerable

(J. Harris: Obviously the general was immunocompromised by his Multiple Myeloma and/or Chemo. RIP to a good man.

FROM BECKER:

VACCINE COVERAGE COMPARISONS

FROM HOPKINS:

Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: Interim Results of a Large-scale, Double-blind, Randomised, Placebo-controlled Phase 2 Trial in Taiwan (Lancet Respiratory Medicine) MVC-COV1901, a recombinant protein vaccine containing pre-fusion-stabilised spike protein S-2P adjuvanted with CpG 1018 and aluminium hydroxide, has been shown to be well tolerated with a good safety profile in healthy adults aged 20–49 years in a phase 1 trial, and provided a good cellular and humoral immune responses. We present the interim safety, tolerability, and immunogenicity results of a phase 2 clinical trial of the MVC-COV1901 vaccine in Taiwan.

FROM ETBU WHERE COVID IS RARE:

AND LAST BUT NOT LEASED: 

***********************************

GIVE US YOUR FEEDBACK.  CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.

Click here to submit feedback.  Let us know what you think.

click here to CLOSE THIS PAGE

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s